 SAPPHIRE will use autologous progenitor cell-based gene delivery to enhance lung microvascular repair and regeneration in patients with severe symptomatic PAH. A total of 45 patients will be enrolled in this multi-centre, phase II, randomized, double-blind, placebo-controlled, 3-arm protocol. Up to seven centres across Canada will participate. 